A study from Sweden published BMJ today there is an increased risk of deep vein thrombosis (bleeding in the leg) up to three months after exposure to COVID-19, pneumonia (bleeding in the lungs) for up to six months, and bleeding up to two months. .
The results of the study also show a high risk of developing complications patients with mild conditions (diseases), patients with severe COVID-19, and during the first epidemic compared with the second and third.
The researchers said that these results support measures to prevent thrombotic events (thromboprophylaxis), especially in critically ill patients, and strengthen the immune system of COVID-19.
It is a well-known fact that COVID-19 increases the risk of developing high blood pressure (known as venous thromboembolism or VTE), but little evidence exists on how long this risk increases, if the risk changes during a disaster trip, and whether COVID-19 also increases the risk of major bleeding.
To address these uncertainties, researchers set out to measure the risk of acute thrombosis. huhu embolismand bleeding after COVID-19.
Using the national register in Sweden, they found more than one million people confirmed to be infected with SARSCoV-2 (the virus responsible for COVID-19) between 1 February 2020 and 25 May 2021, which is appropriate and age, sex, and district over 4 million People who did not receive valid SARS-CoV-2 test results.
They then performed two studies: initially, they calculated the value of deep thrombosis, lung. embolismand bleeding in humans with COVID-19 during control (before and long after COVID-19 infection) and compared with values at different intervals after detection of COVID-19 (days 1-7, 8) -14, 15-30), 31-60, 61-90, and 91-180).
In the second study, they quantified the severity of acute thrombosis, pulmonary edema, and bleeding within 1–30 days after exposure to COVID-19 in the COVID-19 group and compared them with normal values in care team.
The results showed that compared with control time, the risk was significantly increased 90 days after COVID-19 for acute thrombosis, 180 days for pulmonary edema, and 60 days for bleeding.
After considering a variety of potential factors, the researchers found an increase in the risk of deep vein thrombosis, a 33-fold increase in the risk of pulmonary embolism, and an almost double increase in the risk of stroke. bleeding within 30 days after infection. .
In absolute terms, this means that the first deep thrombosis occurred in 401 patients with COVID-19 (absolute risk 0.04%) and 267 patients (absolute risk 0.01%). One case of primary pulmonary edema occurred in 1,761 patients with COVID-19 (absolute risk 0.17%) and 171 patients (absolute risk 0.004%), and a primary hemorrhagic event occurred in patients. healthy 1,002 with COVID-19 (absolute risk 0.10%) and 1,292 patient caregivers (absolute risk 0.04%).
The risk was higher in patients with severe COVID-19 and during the first epidemic compared with the second and third waves, which the researchers said could be explained by increased risk treatment and vaccination in elderly patients after the first resurrection.
Even among COVID-19 cohort patients, the researchers found an increased risk of deep vein thrombosis. thrombosis da huhu embolism. There was no increased risk of bleeding in mild cases, but there was a noticeable increase in more severe cases.
This is a observational study, so researchers cannot establish a reason, and accept many limitations that may affect their research. For example, VTE may not be detected in patients with COVID-19, COVID-19 testing is limited, especially during the first trip, and no data on immunization are available.
However, the results are consistent after further research, and are consistent with similar studies on the association between COVID-19 and thromboembolic events, suggesting that they tolerate research.
Therefore, the researchers said their findings show that COVID-19 is an independent substance deep vein thrombosispneumonia, bleeding, and the risk of these effects increases for three, six, and two months after COVID-19, respectively.
“Our findings have strong evidence supporting thromboprophylaxis to avoid thrombotic events, especially in critically ill patients, and to strengthen the immune system of COVID-19,” they said.
In a related editorial, researchers at the University of Glasgow point out that despite the potential for new gender differences, many governments are removing restrictions and turning their attention to determining how best to “live with COVID.”
However, they say this study “reminds us of the need to remain vigilant about complications associated with mild SARS-CoV-2 infection, including thromboembolism.”
Studies have found an increase in the risk of severe blood clots up to six months after COVID-19, BMJ, DOI: 10.1136 / bmj-2021-069590
British Medical Journal
hintResearch has found an increased risk of developing high blood pressure up to six months after the return of COVID-19 (2022, April 6) 6 April 2022 from https://medicalxpress.com/news/2022-04-blood-clots- months-covid- .html
This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.
Study finds increased risk of serious blood clots up to six months after COVID-19 Source link Study finds increased risk of serious blood clots up to six months after COVID-19